We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Axela Licenses Beckman's Universal Linker Capture Technology

By Labmedica staff writers
Posted on 20 Dec 2006
Axela Biosensors Inc. More...
(Toronto, Canada), and Beckman Coulter Inc. (Fullerton, CA, USA), have announced the signing of a nonexclusive licensing agreement that gives Axela rights to Beckman Coulter's patented A2 universal linker capture technology. The terms of the license were not disclosed. Axela will incorporate the technology into its dotLab Sensors, which will give scientists the unique ability to create user-defined multiplex biomarker panels.

Combining A2 universal linkers with the recently launched dotLab System allows scientists to create custom multiplex protein assays without the need for specialized pipetting or spotting techniques. Axela plans to use the technology in conjunction with its dotLab sensors to allow users to define their own biomarker panels and to use either the Axela library of pre-conjugated antibodies or their own reagents with universal linkers.

"The innovative Universal Linker approach will allow users to tag their own antibodies or draw from a library of existing markers to build combined assays with micromolar to picomolar sensitivity requirements,” explained Rocky Ganske, CEO of Axela Biosensors.

"Coupled with the dotLab System, this self-addressing DNA approach gives the translational scientist a simple and flexible method to perform multiplexed immunoassays, and has the potential to significantly transform the speed in which putative biomarkers can be validated.”

Axela Biosensors is commercializing products that accelerate the validation of protein biomarkers from discovery into routine clinical practice. The company has developed a proprietary breakthrough technology called diffractive optics technology (dot), which enables the real-time detection and quantitation of protein-binding events in complex media. Axela developed this technology into the dotLabSystem, a commercially available benchtop laboratory system that delivers simple, affordable, yet highly sensitive protein based assays. To leverage the opportunities that dot creates, Axela has assembled a management team with extensive experience in diagnostic and research product development and commercialization.

Beckman Coulter, Inc. manufactures biomedical testing instrument systems, tests, and supplies that simplify and automate laboratory processes.



Related Links:
Axela Biosensors
Beckman Coulter

Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Chlamydia Trachomatis Test
Aptima Chlamydia Trachomatis Assay
New
Automatic Hematology Analyzer
LABAS F9000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Molecular Diagnostics

view channel
Image: The discovery of early markers for ovarian cancer that would have improved sensitivity could aid detection (Photo courtesy of Adobe Stock)

Highly Accurate Biomarkers Could Detect Ovarian Cancer Before Clinical Diagnosis

Ovarian cancer is a deadly and challenging disease, primarily because early detection is difficult. Most women (70-75%) are diagnosed only after the cancer has already spread, which significantly reduces... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: CellLENS enables the potential precision therapy strategies against specific immune cell populations in the tissue environment (Photo courtesy of MIT)

New AI System Uncovers Hidden Cell Subtypes to Advance Cancer Immunotherapy

To produce effective targeted therapies for cancer, scientists need to isolate the genetic and phenotypic characteristics of cancer cells, both within and across different tumors. These differences significantly... Read more

Technology

view channel
Image: The Check4 gene-detection platform (Photo courtesy of IdentifySensors)

Electronic Biosensors Used to Detect Pathogens Can Rapidly Detect Cancer Cells

A major challenge in healthcare is the early and affordable detection of serious diseases such as cancer. Early diagnosis remains difficult due to the complexity of identifying specific genetic markers... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.